AR034324A1 - Composicion farmaceutica que posee caracteristicas farmacocineticas incrementadas - Google Patents

Composicion farmaceutica que posee caracteristicas farmacocineticas incrementadas

Info

Publication number
AR034324A1
AR034324A1 ARP020101639A ARP020101639A AR034324A1 AR 034324 A1 AR034324 A1 AR 034324A1 AR P020101639 A ARP020101639 A AR P020101639A AR P020101639 A ARP020101639 A AR P020101639A AR 034324 A1 AR034324 A1 AR 034324A1
Authority
AR
Argentina
Prior art keywords
component
therapeutic
mixtures
derivatives
therapeutic component
Prior art date
Application number
ARP020101639A
Other languages
English (en)
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR034324A1 publication Critical patent/AR034324A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición farmacéutica que consta de: un componente terapéutico en una cantidad terapéuticamente eficaz y un componente que mejora la disposición farmacocinética del componente terapéutico, dicho componente se selecciona del grupo integrado por polímeros aniónicos , ácidos grasos,, derivados de los mismo, el componente que mejora la eficacia forma un complejo con el componente terapéutico y mezclas del mismo, el complejo permanece sustancialmente intacto en un medio acuoso. El componente terapéutico consta de un agonista alfa-2 adrenérgico, antagonista NMDA, antibacterianos, antihistamínicos, descongestivos, antiinflamatorios, adrenenérgicos, antivirales, anestésicos locales, antihongos, amebicidas, tricomonocidas, analgésicos, midriáticos, drogas antiglaucoma, inhibidores carbónico anhidrasa, agentes para diagnóstico oftálmico que se emplean como adyuvantes en cirugía, agentes quelantes, antineoplásicos, antihipertensivos, relajantes musculares, diagnósticos, derivados y mezclas de los mismos. El compuesto mejorador de la eficacia se selecciona del grupo que incluye un ácido linolénico, derivados y mezclas de los mismos. Dicho compuesto mejorador puede poseer un efecto terapéutico y se halla, o no en un complejo con el componente terapéutico.
ARP020101639A 2001-05-03 2002-05-03 Composicion farmaceutica que posee caracteristicas farmacocineticas incrementadas AR034324A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/847,935 US20020198209A1 (en) 2001-05-03 2001-05-03 Compositions having enhanced pharmacokinetic characteristics

Publications (1)

Publication Number Publication Date
AR034324A1 true AR034324A1 (es) 2004-02-18

Family

ID=25301876

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP020101639A AR034324A1 (es) 2001-05-03 2002-05-03 Composicion farmaceutica que posee caracteristicas farmacocineticas incrementadas

Country Status (3)

Country Link
US (2) US20020198209A1 (es)
JP (1) JP2010132681A (es)
AR (1) AR034324A1 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0213027D0 (en) * 2002-06-07 2002-07-17 Jsr Farming Group Compound
CN1684701B (zh) 2002-07-30 2012-10-17 奥默罗斯公司 眼科冲洗液及方法
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
US20040191332A1 (en) * 2003-03-27 2004-09-30 Allergan, Inc. Preserved ophthalmic compositions
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
WO2005014046A2 (en) 2003-08-07 2005-02-17 Allergan, Inc. Compositions for delivery of therapeutics into the eyes and methods for making and using the same
US7411601B2 (en) * 2004-08-03 2008-08-12 Seiko Epson Corporation Exposure head
US9125807B2 (en) 2007-07-09 2015-09-08 Incept Llc Adhesive hydrogels for ophthalmic drug delivery
US7842714B2 (en) 2008-03-03 2010-11-30 Allergan, Inc. Ketorolac tromethamine compositions for treating ocular pain
US9192571B2 (en) * 2008-03-03 2015-11-24 Allergan, Inc. Ketorolac tromethamine compositions for treating or preventing ocular pain
EP2396070A4 (en) 2009-02-12 2012-09-19 Incept Llc ACTIVE COMPOSITION WITH HYDROGEL PLUGS
EP2329849B1 (en) 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
US8394800B2 (en) * 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
AU2011231544B2 (en) 2010-03-26 2015-01-15 Galderma Research & Development Improved methods and compositions for safe and effective treatment of telangiectasia
ES2627405T3 (es) 2010-03-26 2017-07-28 Galderma Research & Development Composiciones que comprenden brimonidina para el tratamiento del eritema
EP3195858B1 (en) 2010-04-03 2019-08-07 Praful Doshi Medical devices including medicaments and methods of making and using same
US10413506B2 (en) 2010-04-03 2019-09-17 Praful Doshi Medical devices including medicaments and methods of making and using same including enhancing comfort, enhancing drug penetration, and treatment of myopia
US8492557B2 (en) 2010-09-16 2013-07-23 Allergan, Inc. Ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol
US8961501B2 (en) 2010-09-17 2015-02-24 Incept, Llc Method for applying flowable hydrogels to a cornea
DK2444068T4 (en) 2010-10-21 2018-03-05 Galderma Sa Brimonide sub-composition
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
US20130046003A1 (en) 2011-07-22 2013-02-21 Mohammed I. Dibas Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating retinal diseases
WO2013016072A1 (en) 2011-07-22 2013-01-31 Allergan, Inc. Pharmaceutical compositions comprising 4-bromo-n-(imidazolidin-2-ylidene)-1h-benzimidazol-5-amine for treating skin diseases
US10226417B2 (en) 2011-09-16 2019-03-12 Peter Jarrett Drug delivery systems and applications
UA109359C2 (xx) 2011-11-10 2015-08-10 Лікування захворювань і станів шкіри 7-(1h-імідазол-4-ілметил)-5,6,7,8-тетрагідрохіноліном
US9283217B2 (en) 2011-11-10 2016-03-15 Allergan, Inc. Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
EP2782569A1 (en) 2011-11-21 2014-10-01 Allergan, Inc. Pharmaceutical compositions comprising 4-[1-(2,3-dimethylphenyl)ethyl]-3h-imidazole derivatives for treating retinal diseases
JP2014533732A (ja) 2011-11-28 2014-12-15 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 網膜神経保護のための７−（１ｈ−イミダゾール−４−イルメチル）−５，６，７，８−テトラヒドロ−キノリンを含む医薬組成物
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
US10350161B2 (en) 2013-10-15 2019-07-16 Pharmathen S.A. Preservative free pharmaceutical compositions for ophthalmic administration
FR3000391B3 (fr) 2013-11-12 2015-02-20 Pharmathen Sa Compositions pharmaceutiques sans conservateur pour administration ophtalmique
TWI809304B (zh) 2014-12-01 2023-07-21 奥默羅斯公司 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液
CN106792076B (zh) * 2015-11-20 2020-04-21 腾讯科技（北京）有限公司 一种进行信息展示的方法、装置和***
WO2018209051A1 (en) 2017-05-11 2018-11-15 Nevakar Inc. Atropine pharmaceutical compositions
US10945982B1 (en) * 2018-05-03 2021-03-16 Paul A. Lobel Nasal hygiene method and composition
US11110056B1 (en) 2018-05-03 2021-09-07 Actual Natural Health & Wellness Products, Inc. Nasal hygiene method and composition
EP3860600A4 (en) * 2018-10-06 2022-07-20 Biotheravision, Inc OPHTHALMIC PREPARATIONS OF A MUSCARINA GONIST AND METHOD OF USE
TWI809317B (zh) * 2020-09-29 2023-07-21 美商百歐賽那生技公司 蕈毒鹼性促效劑眼用製劑及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188393A (en) 1977-04-22 1980-02-12 Sandoz Ltd. Treating spastic conditions or relaxing muscles
DE3309765A1 (de) 1983-03-18 1984-09-20 Bayer Ag, 5090 Leverkusen Fungizide mittel
US4683325A (en) 1984-01-23 1987-07-28 Merck Frosst Canada, Inc. Leukotriene antagonists
US4761425A (en) 1983-12-27 1988-08-02 Merck Frosst Canada, Inc. Leukotriene antagonists
US4629621A (en) 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4617407A (en) 1984-08-30 1986-10-14 Merck Frosst Canada, Inc. Leukotriene antagonists
US5118493A (en) * 1986-05-02 1992-06-02 Brigham And Women's Hospital Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine
US4885309A (en) 1986-08-01 1989-12-05 Hoffmann-La Roche Inc. Therapeutic treatment of leukotriene-mediated dermal inflammation by topical administration of 3,4-dihydro-2H-1-benzopyran derivatives
JP2563336B2 (ja) * 1987-06-01 1996-12-11 エーザイ株式会社 角膜透過促進点眼剤
DE3729299A1 (de) 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
JPH0283314A (ja) * 1988-09-20 1990-03-23 Zeria Pharmaceut Co Ltd 安定な脂溶性物質の水溶液
US5256680A (en) 1988-11-29 1993-10-26 Warner-Lambert Company 3,5-di-tertiary-butyl-4-hydroxyphenyl-1,3,4-thiadiazoles, and oxadiazoles and 3,5-di-tertiary-butyl-4-hydroxy-phenyl-1,2,4-thiadazoles, oxadiazoles and triazoles as antiinflammatory agents
US5180721A (en) * 1989-05-22 1993-01-19 Allergan, Inc. Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure
JPH085779B2 (ja) * 1989-09-22 1996-01-24 杏林製薬株式会社 フレロキサシン点眼液
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
US5093356A (en) 1990-01-16 1992-03-03 Merck Frosst Canada, Inc. Indenyl hydroxamic acids and hydroxy ureas as inhibitors of 5-lipoxygenase
US5276044A (en) * 1991-08-14 1994-01-04 Allergan, Inc. Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions
DE69311361T2 (de) * 1992-10-13 1998-01-08 Alcon Lab Inc Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten
US6117871A (en) * 1993-12-17 2000-09-12 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists
JPH09506622A (ja) * 1993-12-17 1997-06-30 ザ、プロクター、エンド、ギャンブル、カンパニー α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノキサリン化合物
US6294563B1 (en) * 1994-10-27 2001-09-25 Allergan Sales, Inc. Combinations of prostaglandins and brimonidine or derivatives thereof
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US5916900A (en) 1995-06-29 1999-06-29 The Procter & Gamble Company 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
CA2259418A1 (en) 1996-07-11 1998-01-22 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
US5962462A (en) 1996-12-13 1999-10-05 Merck & Co., Inc. Spiro-substituted azacycles as modulators of chemokine receptor activity
GB9700555D0 (en) 1997-01-13 1997-03-05 Merck Sharp & Dohme Therapeutic agents
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
JP3607062B2 (ja) 1997-10-24 2005-01-05 株式会社コーセー 脂肪蓄積抑制剤及びそれを含有する皮膚外用剤
JPH11185650A (ja) * 1997-12-18 1999-07-09 Toshiba Corp カラー受像管
TW537895B (en) * 1998-08-21 2003-06-21 Senju Pharma Co Aqueous solution preparation containing gatifloxacin
EP1109581A1 (en) * 1998-09-02 2001-06-27 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US6416786B1 (en) 1998-12-11 2002-07-09 Nostrum Pharmaceuticals, Inc. Sustained release tablet containing hydrocolloid and cellulose ether
US6242442B1 (en) * 1998-12-17 2001-06-05 Alcon Laboratories, Inc. Brinzolamide and brimonidine for treating ocular conditions
US6258350B1 (en) * 1999-01-20 2001-07-10 Alcon Manufacturing, Ltd. Sustained release ophthalmic formulation
AU2727400A (en) 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
IT1313583B1 (it) * 1999-07-30 2002-09-09 Chiesi Farma Spa Derivati 2-amminotetralinici per la terapia del glaucoma.
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
RU2311928C2 (ru) * 2000-07-14 2007-12-10 Аллерган Инк. Композиции, содержащие альфа-2-адренергические агонисты
US6673802B2 (en) * 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US20020198210A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Alpha-2-adrenergic agonist/fatty acid compositions
US20050191245A1 (en) * 2004-02-27 2005-09-01 Adams Christopher P. Nasal administration of calcium channel, blockers for treatment of hypertension and other cardiovascular disorders

Also Published As

Publication number Publication date
US7491383B2 (en) 2009-02-17
JP2010132681A (ja) 2010-06-17
US20030017199A1 (en) 2003-01-23
US20020198209A1 (en) 2002-12-26

Similar Documents

Publication Publication Date Title
AR034324A1 (es) Composicion farmaceutica que posee caracteristicas farmacocineticas incrementadas
Seymour et al. The efficacy of ketoprofen and paracetamol (acetaminophen) in postoperative pain after third molar surgery
CY1118505T1 (el) Στερεη φαρμακευτικη μορφη δοσολογιας περιλαμβανουσα στερεη διασπορα αναστολεα πρωτεασης hiv
DE60232417D1 (de) Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
CY1109070T1 (el) Διαδερμικη μορφη δοσολογιας περιλαμβανουσα ενα δραστικο παραγοντα και ενα αλας και μια μορφη ελευθερης βασεως ενος ανταγωνιστη
DK1256343T3 (da) Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
BRPI0511224A (pt) método para preparar uma composição contendo antagonistas de opióides, produto contendo antagonistas de opióides, composição contendo antagonistas de opióides, formulação de dosagem injetável, kit, método para prevenir ou tratar um efeito colateral associado com um opióide num paciente, e para tratar ou impedir dor num paciente
DE60320530D1 (de) Missbrauchssichere transdermale opioid-verabreichungsvorrichtungen
AR045039A1 (es) Dispositivo de administracion de drogas oftalmicas
WO2005044178A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
LU92323I2 (fr) La combinaison de (a) dextromethorphan ou un de ses sels pharmaceutiquement acceptables, précursers ou dérivés, par ex. hydrobromure de dextromethorphan et en particulier hydrobromure de dextromethorphan monohydrate;et (b) quinidine ou un de ses selspharmacuetiquement acceptables, précurseurs ou dé rivés, par ex. sulfate de quinidine et en particulier sulfate de quinidine dihydrate
CY1115869T1 (el) Χρηση ανταγωνιστων του υποδοχεα τυπου 1 της αγγειοτενσινης ii για την προληψη του διαβητη
HRP20020158B1 (en) Action of synergistic combination
SE0002754D0 (sv) New pharmaceutical combination formulation and method of treatment with the combination
BRPI0113757B8 (pt) derivados de quinolinona como inibidores de tirosina quinase
AR048439A1 (es) Composiciones farmaceuticas y metodos para tratar la infeccion por vih
ECSP066878A (es) [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa
RU2004135563A (ru) Лекарственное средство для лечения повышенной активности мочевого пузыря
DE602004019653D1 (de) Eine Missbrauch verhinderende, transdermale Dosierungsform, die einen Wirkstoff und einen Antagonisten des Wirkstoffs enthält
TW200616606A (en) Treatment and prevention of multi-drug resistance
NO20051261L (no) Morfin-6-glukuronidsalt
TW200420290A (en) Methods for the treatment, prevention and management of macular degeneration
AR032422A1 (es) Uso de inhibidores de il-18 para el tratamiento y/o prevencion de la enfermedad cardiaca
AR038858A1 (es) Combinacion
UY29989A1 (es) Composiciones farmacéuticas de agentes hipnoticos de accion corta en forma de liberación modificada y los procedimientos para preparar dichas formulaciones

Legal Events

Date Code Title Description
FB Suspension of granting procedure